Cancer treatment company Sirtex in trading halt ahead of deal announcement

Cancer treatment company Sirtex in trading halt ahead of deal announcement
Shares in Sirtex Medical (ASX: SRX) have been placed in a trading halt as it prepares to release to the market details of a "potential material corporate transaction".

The liver cancer treatment specialist, which has been touted as a potential takeover target in recent weeks, gave no further details of the deal and requested the trading halt until the opening of trade on Thursday or the release of its announcement, depending on which comes first.

Sirtex shares have surged more than 20 per cent over the past three weeks on the back of strong first half earnings of $34 million, which was a 16 per cent increase on the prior corresponding period.

The company reported a $26.3 million loss in 2016-17 after writedowns and failed clinical trials.

Sirtex shares were $18.83 at Monday's close which is at its highest price since late 2016.

Sales of the company's SIR-Spheres microspheres, a product used to deliver medication to cancer sites inside the body, were flat in the first half but McLean says the company expects higher sales in the second half of 2017-18.

"As a result of recent management initiatives, we anticipate higher sales in the second half, with ongoing targeted reductions in operating expenditure to drive business efficiencies and productivity gains, resulting in forecasted full year EBITDA (earnings before interest, tax, depreciation and amortisation) in the range of $75 to $85 million," McLean says.

This compares to an underlying EBITDA of $61.5 million in the 2017 financial year.


Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Get our daily business news

Sign up to our free email news updates.

 
Unpacking equity: Finding your funding fit
Partner Content
Armed with a growing business and a great opportunity, a business owner’s next challe...
Australian Business Growth Fund
Advertisement

Related Stories

Meta slammed over "dereliction" of commitment to Australian news

Meta slammed over "dereliction" of commitment to Australian news

The decision by Meta (NASDAQ: META) to "deprecate" the Fa...

AF Legal acquires Armstrong Contested Wills & Estates in deal worth up to $3.75m

AF Legal acquires Armstrong Contested Wills & Estates in deal worth up to $3.75m

A year on from the failure of an $11 million merger with Go to Cour...

GreenCollar buys into EnergyLink Services to tackle agribusiness decarbonisation

GreenCollar buys into EnergyLink Services to tackle agribusiness decarbonisation

Environmental markets project developer GreenCollar has made a stra...

Childcare veteran Chris Scott scaling up Embark Early Education with $25m acquisition

Childcare veteran Chris Scott scaling up Embark Early Education with $25m acquisition

Embark Early Education (ASX: EVO), a Gold Coast-based childcare cen...